INTRODUCTION
Asthma and chronic obstructive pulmonary disease (COPD) are the most common respiratory diseases in the clinic. Patients having bronchial obstruction due to inflammation in the airways, often present with clinical symptoms such as dyspnea, respiratory restriction, and cough. 1, 2 Related studies have shown that there are certain overlaps in the pathogenesis, clinical symptoms, and predisposing factors of asthma and chronic obstructive pulmonary disease. 3 This overlap is referred to as asthma-chronic obstructive pulmonary overlap syndrome (ACOS). 4 At present, many medicines are mainly used for the treatment of ACOS clinically, but there is no consensus as for which medicine to use. Glucocorticoid inhalation is a common method for the treatment of ACOS. Although it can improve the patient's lung function, the efficacy is not very satisfactory for most patients. 5 Therefore, actively exploring effective treatment plan for ACOS is one of the urgent medical problems clinically. Tiotropium bromide is a bronchodilator suitable for the maintenance treatment of chronic obstructive pulmonary disease. 6 The objective of this study was to compare the efficacy of inhaled glucocorticoid with or without tiotropium bromide in the treatment of patients with asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
received hormone therapy and used leukotrienes receptor antagonists, 2-agonists, anticholinergic agents within 2 weeks before treatment, were excluded.
All patients were divided into the control group and the observation group using a random number table method, with 43 cases in each group; and received conventional treatment, including control of exercise load, home oxygen therapy or oxygen inhalation. Among them, the control group was treated with inhaled glucocorticoid; that is, budesonide glucocorticoid 100 g per inhalation, 2 times/day. Patients in the observation group were treated with tiotropium bromide on the basis of the control group. Before use, 1 tiotropium bromide capsule (18 g/ capsule) was put into the puncture slot of a special inhaler. The button was pressed with a finger. Both ends of the capsule were punctured with fine needles. The mouthpiece was put deep into the mouth for inhalation. The capsule rotated rapidly with the airflow. The powder in the capsule was ejected and entered the respiratory tract with the airflow. The dosage used was one capsule once a day. Both groups of patients were treated for six months.
The asthma control test (ACT) score and the chronic obstructive pulmonary disease assessment test (CAT) score were compared between the two groups before and after treatment. ACT score and CAT score were conducted by face-to-face interviews between doctors and patients. The total ACT score was 25 points. The higher the score, the less serious the patient's condition was. The total CAT score was 40 points. The higher the score, the more serious the patient's condition was.
Before and after treatment, 5 mL of fasting venous blood was collected from patients in a state of quietness, and the levels of serum high-sensitivity C-reactive protein (hs-CRP) and IL-6 were detected by enzyme-linked immunosorbent assay. The incidence of adverse reactions during the treatment was observed.
Data was analysed in SPSS version 21. Mean value ±SD was calculated for numericals like ACT score, CAT score, levels of serum hs-CRP and IL-6, examined by independent sample t-test. Frequencies and percentages were calculated for categorical variables like gender, history of smoking and incidence of adverse reactions. Chi-square test was applied to compare the categorical variables in two groups. Results were considered significant at p<0.05.
RESULTS
Among the 86 patients, 50 were males (58.14%) and 36 were females (41.86%); aged 42-74 years, mean age 63.71 ±2.45 years. The duration of disease ranged from 6-28 months with mean duration 14.53 ±3.02 months. Patients with a history of smoking were 58 (67.44%). The number of patients with acute exacerbation in 2 years was 1-5 (3.4 ±1.5) times.
Before treatment, there was no significant difference in ACT score and CAT score between the two groups (P=0.808, 0.947, respectively). After treatment, ACT score was higher in the observation group than that in the control group (p<0.001), and CAT score was lower than that in the control group (p<0.001, Table I ).
Before treatment, there was no significant difference in serum hs-CRP and IL-6 levels between the two groups (p=0.872 and 0.921, respectively). After treatment, serum levels of hs-CRP and IL-6 were lower in the observation group than those in the control group (both p<0.001, Table II ).
The incidence of adverse reactions, such as dry mouth, heart palpitations, hoarseness, dysuria, and oral candidiasis 
DISCUSSION
Glucocorticoids suppress immune responses and prevent inflammation, virus and shock, and are widely used in the treatment of asthma because of its strong anti-inflammatory and anti-allergic effects. 8 Budesonide is a typical representative of this class of medicines.
With better local anti-inflammatory effect, it can effectively improve the patient's clinical symptoms and lung function, as well as inhibit the patient's airway inflammation. 9, 10 Tiotropium bromide is a highly effective, long-acting anticholinergic drug that selectively acts on patients' M1 and M2 receptors. It has a longlasting and mild effect with a low incidence of adverse reactions. It can not only effectively alleviate the clinical response of asthma-COPD patients during the disease, but also improve the patient's lung function and expand bronchial smooth muscle. 11, 12 This study showed that after treatment, ACT score of the observation group was higher than that of the control group, and CAT score was lower than that of the control group. It suggested that inhaled glucocorticoid combined with tiotropium bromide can effectively relieve the clinical symptoms of ACOS patients and help control the development of the disease. It also showed that the incidence of adverse reactions was lower in the observation group than that in the control group, suggesting that inhaled glucocorticoid combined with tiotropium bromide in the treatment of ACOS has relatively high safety. This general conclusion is consistent with previous research suggesting that tiotropium bromide is a safe and effective treatment choice for moderate-to-severe COPD. 13 The hs-CRP is an acute phase protein synthesised by liver cells when the body is subjected to inflammatory stimuli such as microbial invasion or tissue damage, and it is not affected by radiotherapy, chemotherapy, and corticosteroid treatment. 14 When the inflammatory reaction occurs in the respiratory tract, hs-CRP levels can indirectly reflect the degree of airflow limitation in the patient. 15, 16 Mainly secreted by monocytes, IL-6 can promote the aggregation and activation of inflammatory cells, the expression of adhesion molecules, and participate in the inflammatory reaction. 17 Studies have shown that the pathogenic mechanism of ACOS may be related to inflammatory reactions in the body. In the present study, serum levels of hs-CRP and IL-6 were lower in the observation group than those in the control group after treatment. This can effectively prove that the combination of inhaled glucocorticoid and tiotropium bromide in the treatment of ACOS patients can significantly reduce the level of serum inflammatory factors, relieve the inflammatory response in vivo, and promote the favourable outcome of the disease. The combination of inhaled glucocorticoid and tiotropium bromide exerts synergistic effects in a variety of mechanisms and has a good therapeutic effect on clinical treatment of ACOS patients.
There are some limitations of this study. First, the sample size is relatively small. Second, the severity of the disease in subjects are not grouped and only mentioned on the basis of symptoms score as mean values. Thirdly, there is no comparison between the two groups in lung functions or quality of life assessment, 6-minute walk test, etc. These limitations can be studied further in future.
CONCLUSION
Compared with inhaled glucocorticoid, inhaled glucocorticoid combined with tiotropium bromide treatment can more effectively reduce the serum levels of hs-CRP and IL-6, which is beneficial to control the development of ACOS.
